Envoy Medical Hits Key Trial Milestone: All 56 Patients Pass 3-Month Mark
COCH sits 95% above its 52-week low of $0.363.
Summary
Envoy Medical announced that all 56 patients in its pivotal Acclaim cochlear implant trial have surpassed the three-month visit milestone. This follows the July 14 report of 12-month data from the first 10 patients, showing the trial is progressing on schedule. The company is now collecting safety and other measures for its planned PMA submission to the FDA. With a market cap around $52 million and ongoing going concern doubts, each clinical milestone is critical for the company's regulatory path and funding prospects. The next major milestones are the six-month visit by late 2026 and the 12-month visit for the full cohort by April 2027.
At the time of this announcement, COCH was trading at $0.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $51.6M. The 52-week trading range was $0.36 to $1.89. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: TMX Newsfile.